FDA
-
-
-
-
-
-
-
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
-
-
-
-
-
-
-
Elanco gets FDA approval for expanded Credelio labels against Lyme disease
-
-
-
-
-
-
-
Elanco Releases 2024 Impact Report and Introduces New Framework
-
-
-
-
-
-
-
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Elanco Animal Health (NYSE: ELAN) Investors to Inquire About a Securities Fraud Class Action by December 6, 2024
-
-
-
-
-
-
-
Piper Sandler Reiterates Neutral Rating on Elanco Animal Health (ELAN)
-
-
-
-
-
-
-
ELAN FRAUD REVIEW: BFA Law Alerts Elanco (NYSE:ELAN) Investors that Lost Money to Contact Us about Securities Fraud Investigation
-
-
-
-
-
-
-
Elanco Announces FDA Has Completed Review of Bovaer(R), First-in-Class Methane-Reducing Feed Ingredient, for U.S. Dairy Industry
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

